Slide 1: ChromaDex Earnings Conference Call Fourth Quarter 2022
ChromaDex Earnings Conference Call Fourth Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 8, 2023
Slide 2: Safe Harbor Statement
2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 19
Slide 3: Q4 2022 & Recent Highlights
3 Q4 2022 & Recent Highlights (1) See slide 12 for the non-GAAP reconciliation Delivered on business and financial objectives, with an emphasis on bottom line in the current macroeconomic environment. In 2023, expect to make investments in targeted brand building initiatives and R&D to drive future
Slide 4: Management Team
4 Management Team Rob Fried Chief Executive Officer E-commerce & entertainment industry executive Savoy Pictures, Columbia Pictures, Fried Films, FeeIn, WHN, Healthspan Research Fadi Karam Chief Marketing Officer Former Nestlé executive Deep brand building experience, across traditional retail as we
Slide 5: Financial Highlights
5 Financial Highlights
Slide 6: Q4 2022 Net Sales Mix
6 Q4 2022 Net Sales Mix E-commerce 63% Watson's & Other B2B 17% Niagen® Ingredient 14% Analytical Reference Standards & Services 5% Other Ingredients 1% $ 17.8 MM Q4 2021Q4 2022 • Tru Niagen® net sales decreased to 77% of net sales in Q4 2022 compared to 80% in Q4 2021(1) • Niagen®-related net sales
Slide 7: Q4 2022 Net Sales
7 Q4 2022 Net Sales Q4 2022 Net Sales ($ in millions) $16.1 11.1 5.0 3.9 0.9 0.1 E-commerce Watson's & Other B2B Niagen® Ingredient Analytical Reference Standards & Services Other Ingredients Total net sales up 18% year-over-year and 23% sequentially driven by growth in Watson's / Other B2B and Niag
Slide 8: Full Year 2022 Net Sales
8 Full Year 2022 Net Sales FY 2022 Net Sales ($ in millions) Total +7% +8% —% +24% (6)% (31)% YoY % (vs FY 2021) $60.1 45.3 14.8 8.3 3.2 0.4 E-commerce Watson's & Other B2B Niagen® Ingredient Analytical Reference Standards & Services Other Ingredients Strong growth in Tru Niagen® from E-commerce, pa
Slide 9: 2020 – 2022 Net Sales Summary
9 2020 – 2022 Net Sales Summary (in millions) 2020 2021 2022 Description Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY E-commerce 8.2 8.1 8.7 9.5 34.5 9.6 10.6 10.5 11.1 41.8 10.9 12.0 11.3 11.1 45.3 Watson's 1.8 1.3 2.5 2.1 7.6 1.6 2.9 2.6 2.2 9.3 2.6 1.5 2.6 3.3 10.0 Other B2B 1.1 2.3 0.8 0.8 5.0 1
Slide 10: Q4 2022 vs Q3 2022 Key P&L Metrics
10 Q4 2022 vs Q3 2022 Key P&L Metrics (in thousands) Q4 2022 Q3 2022 Notes Net Sales $20,996 $17,063 Tru Niagen® business up 11% and increased Niagen® ingredient sales driven by upfront purchase from Nestlé of $2.0MM. Gross Profit % of Net Sales 12,016 57.2% 10,207 59.8% Gross margin down mainly due
Slide 11: Q4 2022 vs Q4 2021 Key P&L Metrics
11 Q4 2022 vs Q4 2021 Key P&L Metrics (in thousands) Q4 2022 Q4 2021 Notes Net Sales $20,996 $17,759 Tru Niagen® business up 14% driven by increased sales to partners, including a catch-up in shipments to Watson's. Niagen® ingredient sales up 53% year-over-year. Gross Profit % of Net Sales 12,016 57
Slide 12: Adjusted EBITDA Summary
12 Adjusted EBITDA Summary ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Three months ended Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Net loss, as reported $ (5,902) $ (3,711) $ (4,215) $ (6,0
Slide 13: Q4 2022 Operating Loss vs Q4 2021
13 Q4 2022 Operating Loss vs Q4 2021 (5.3) 2.4 2.0 0.4 0.2 (0.1) (0.2) (0.8) (1.4) Q4 2021 Operating Loss Sales & Marketing Volume Legal Equity Comp (G+A) Other G+A Research & Development Gross Margin Decline Q4 2022 Operating Loss (6.0) (5.0) (4.0) (3.0) (2.0) (1.0) — (in millions) +$5.0MM $(1.1) M
Slide 14: Quarterly Balance Sheet Highlights
14 Quarterly Balance Sheet Highlights Invested in future growth, continued to manage working capital. Raised $7.7 million, net of offering costs, in October 2022. (in thousands) 12/31/20 3/31/21 6/30/21 9/30/21 12/31/21 3/31/22 6/30/22 9/30/22 12/31/22 Key Drivers (FY 2022 vs 2021) Cash $16,697 $44,
Slide 15: Quarterly Cash Flow Highlights
15 Quarterly Cash Flow Highlights (in thousands) FY 2020 3/31/21 6/30/21 9/30/21 12/31/21 FY 2021 3/31/22 6/30/22 9/30/22 12/31/2022 FY 2022 Net Loss $ (19,925) $ (7,381) $(5,566) $(8,856) $(5,325) $(27,128) $(7,740) $(6,397) $(985)(3) $(1,418) $(16,540) Working Capital 383 258 (4,390) 942 (1,670) (
Slide 16: 2022 Full Year Outlook Recap
16 2022 Full Year Outlook Recap (in thousands) 2021 Actual 2022 Outlook (1) 2022 Actual Comments Achieved?(2) Net Sales $67,449 High single digits growth YoY $72,050 Total net sales grew by +7% and Tru Niagen® net sales grew by +6% year- over-year ü Gross Margin % (as a % of net sales) 61.5% Approxi
Slide 17: 2023 Financial Outlook
17 2023 Financial Outlook (in thousands) 2021 Actual 2022 Actual 2023 Full Year Outlook Key Drivers Net Sales $67,449 $72,050 At least 10% growth YoY, with realistic possibility of significantly greater growth • Low-end includes steady growth from E- commerce business & recurring revenues from estab
Slide 18: Adjusted EBITDA 2022 vs 2021
18 Adjusted EBITDA 2022 vs 2021 ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Year Ended Year-over-Year ChangeDec 31, 2021 Dec 31, 2022 Net loss, as reported $ (27,128) $ (16,540) $ 10,588 Adjustments Interest (income) expense 55 (3) (58) Depreci
Slide 19: Q4 2022 Financial Highlights - Recap
19 Q4 2022 Financial Highlights - Recap • Total net sales of $21.0 million in Q4 2022 (+18% YoY, +23% versus Q3 2022). • Continued progress building Tru Niagen® into a global brand. ◦ Tru Niagen® net sales of $16.1 million in Q4 2022 (+14% YoY, +11% vs Q3 2022). • Solid gross margin of 57.2% ((400)
Slide 20: The Science
The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) The Science 20
Slide 21: New Human Trials on Nicotinamide Riboside
21 • Five new human trials on nicotinamide riboside registered since prior update:¹ ▪ Haukeland University Hospital (November 2022) • The objective is to determine the optimal dose of NR in individuals with Alzheimer's disease (AD) • Three key questions the trial is aiming to answer are: ▪ What dose
Slide 22: New Human Trials on Nicotinamide Riboside (continued)
22 • University Hospital, Akershus (February 2023) • The objective is to determine whether NR can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline chemotherapy • Breast cancer is the most common form of cancer in women. Modern breast cancer
Slide 23: Recent Peer-Reviewed Clinical Publications
23 • Aging Cell – Vreones et al., 2022 – “Oral Nicotinamide Riboside Raises NAD+ and Lowers Biomarkers of Neurodegenerative Pathology in Plasma Extracellular Vesicles Enriched for Neuronal Origin.” – December 2022 • The study investigated whether NR could positively augment nicotinamide adenine dinu
Slide 24: Recent Peer-Reviewed Clinical Publications
24 Recent Peer-Reviewed Clinical Publications • Translational Neurodegeneration – Yulug et al., 2023 – “Combined Metabolic Activators Improve Cognitive Functions in Alzheimer’s Disease Patients: A Randomized, Double-Blinded, Placebo-Controlled Phase-II Trial.” – January 2023 • The study investigated
Slide 25: Scientific Advisory Board
25 Scientific Advisory Board Charles Brenner, Ph.D. Alfred E Mann Family Foundation Chair, Department of Diabetes & Cancer Metabolism City of Hope World's Foremost Authority on NAD Metabolism Roger Kornberg, Ph.D. Chairman Professor of Structural Biology Stanford University Nobel Prize Winner, Chemi
Slide 26: Basic Physiological Functions are NAD+ Dependent
26 Basic Physiological Functions are NAD+ Dependent INTRINSIC CAPACITY DOMAIN Based on World Health Organization’s definition VITALITY Energy metabolism Hormonal function Cardio-respiratory function Number of clinical trials (active)* 15 Number of clinical trials (complete)* 9 % of all registered Ni
Slide 27: Contact Info
27 Contact Info Tom Shumaker LifeSci Advisors, Managing Director T: +1.917.929.7600 TShumaker@lifesciadvisors.com www.chromadex.com Where to buy TRU NIAGEN® truniagen.com amazon.com